In a new job - May 20, 2022
BerGenBio appoints Chief Medical Officer
BerGenBio has announced the appointment of Cristina Oliva as Chief Medical Officer (CMO). Cristina Oliva joins the senior leadership team heading up clinical development of BerGenBio’s selective AXL inhibitor programs. “I’m delighted to welcome Cristina as our new Chief Medical Officer. Cristina’s leadership experience within oncology drug development across big pharma, biotech and CRO environments […]
In a new job - February 23, 2022
BerGenBio appoints new Chairman of the Board
BerGenBio has announced the appointment of Anders Tullgren to succeed Sveinung Hole as Chairman of the Board of Directors. Sveinung Hole has been Chairman of the Board since March 2019 and will continue to serve as a Board Member. “We’re delighted to welcome Anders Tullgren as Chairman. Anders’ experience and deep knowledge of development, commercialization […]
COVID-19 - January 31, 2022
BerGenBio’s bemcentinib will be studied in the EU-SolidAct trial
BerGenBio and Oslo University Hospital have announced the execution of a collaborative agreement to study the BerGenBio AXL inhibitor bemcentinib, in hospitalised COVID-19 patients. The EU-SolidAct trial – European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial – is part of EU-RESPONSE, a pan-European research project involved with the rapid and coordinated […]
Clinical Trials - November 16, 2021
BerGenBio presents new pre-clinical and clinical data
BerGenBio will deliver an e-poster presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting, including pre-clinical and clinical data suggesting that bemcentinib restored response to anti-PD-1 treatments in non-small cell lung cancer (NSCLC) patients harboring STK11 mutations. STK11 is an important tumor suppressor gene reported in some studies to confer immunotherapy resistance […]
Biotech Business - November 9, 2021
BerGenBio receives Fast Track designation
BerGenBio has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for bemcentinib in combination with an anti-PD-(L)1 agent as treatment for patients with STK11 altered advanced/metastatic NSCLC patients without actionable mutations. The Fast Track designation will enable BerGenBio to have more frequent interactions with the FDA throughout the drug […]
In a new job - September 10, 2021
BerGenBio announces leadership changes
BerGenBio has announced the appointment of Martin Olin as new Chief Executive Officer from 8 September 2021. Following twelve years as CEO of BerGenBio, Richard Godfrey has decided to step down as CEO of the company with immediate effect to pursue other business interests. “I have thoroughly enjoyed my past twelve years at BerGenBio and […]
